← All Biogen INC filings

Biogen INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
BIIB
Biogen INC
10-K: Biogen's 2025 Performance: New Launches Offset MS Decline
Biogen reports 2.2% revenue growth in 2025 driven by new rare disease and neuropsychiatry launches, despite continued decline in MS product sales and increased R&D investments.
NASDAQ
BIIB
Biogen INC
10-K: Biogen's 2024 10-K Filing: Strategic Shifts and Pipeline Developments
Biogen's 2024 10-K filing highlights strategic shifts, pipeline advancements, and financial performance in a competitive biopharmaceutical landscape.
NASDAQ
BIIB
Biogen INC
10-K: Biogen's 2023 Annual Report: Strategic Shifts and Financial Performance
Biogen's 2023 annual report details a year of strategic shifts, including acquisitions, pipeline adjustments, and cost-saving measures, alongside a decline in overall revenue.